1. ALLA AKTIER
  2. NYHETER
  3. COMBIGENE

Combigene

Nyheter Combigene Nyheter alla bolag

Interim report January – September 2022 for CombiGene AB (publ)

MARKN.

July – September 2022
•  Net sales: 5,213 (0) TSEK.
•  Other operating revenues: 8,313 (423) TSEK.
•  Profit from financial items: 3,953 (-10,225) TSEK.
•  Earnings per share: 0.20 (-0.52) SEK.

January – September 2022
•  Net sales: 21,354 (0) TSEK.
•  Other operating revenues: 21,280 (6,380) TSEK.
•  Profit from financial items: 5,785 (-36,483) TSEK.
•  Earnings per share: 0.29 (-2.22) SEK.
•  Cash and cash equivalents as per the end of the reporting period: 144,940 (66,087) TSEK.
•  Equity ratio as per the end of the reporting period: 96 (95)%.

Events during the period
• CombiGene strengthens its management capacity through the recruitment of Peter Ekolind as COO.

Events after the end of the period
• There have been no significant events after the end of the period.

Link to the report

Contacts

Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
jan.nilsson@combigene.com

Bert Junno, Chairman of the board
Phone: +46 (0)707 77 22 09
bert.junno@combigene.com

www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
+46-8-357355 info@combigene.com

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
 
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
 
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, info@fnca.se.

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282.
CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714

Attachments

CG Q3 2022 EN

Datum 2022-11-11, kl 09:00
Källa MFN
Bifogade filer
CG Q3 2022 EN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!